TITLE:
National Cooperative Growth Study (NCGS): A Post-marketing Surveillance Program for Nutropin, Nutropin AQ, Nutropin Depot, and Protropin

CONDITION:
Growth Disorders

INTERVENTION:
Somatrem

SUMMARY:

      The purpose of this multicenter, open-label, observational, post-marketing surveillance
      study is to collect long term safety and efficacy information on growth hormone (GH)
      products: Protropin (somatrem for injection), Nutropin (somatropin for injection), Nutropin
      AQ (somatropin for injection), and Nutropin Depot (somatropin for injectable suspension) in
      the treatment of pediatric growth disorders for which GH is prescribed.
    

DETAILED DESCRIPTION:
NONE

ELIGIBILITY:
Gender: All
Age: N/A to N/A
Criteria:

        Inclusion Criteria:

          -  Participants with open epiphyses

          -  Children of either sex who are treated with Nutropin Depot, Nutropin AQ, Nutropin, or
             Protropin for the treatment of growth failure

          -  Participants who are willing to keep follow up appointments throughout the study
             participation

        Exclusion Criteria:

          -  Participants treated with a non-Genentech GH preparation

          -  Participants with closed epiphyses

          -  Participants with active neoplasia
      
